Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
HeXell-2020 in Frailty Syndrome
NCT07144072Phase 1Not yet recruiting
- Sponsor
- HeXun Biosciences
- Start
- Dec 2026
- Primary completion
- Dec 2028
- Modality
- Mesenchymal Stem Cells
01
Overview
Phase 1, open-label trial of HeXell-2020 in frailty syndrome (2 cohorts), sponsored by HeXun Biosciences. Primary endpoints: Maximum Feasible Dose, Treatment-Emergent Adverse Events at 1 year and 1 more. Planned start Dec 2026; status: not yet recruiting.
02
Drugs
HeXell-2020
03
Conditions
frailty syndrome
Beyond the preview
Go deeper on NCT07144072.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07144072.